-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AxlrE2RUpsUEq1/ldga7/y8mRxpvN/vZV9jIy3TsK0eOr7xehP3WF4ObPaWGDupu DZWS6gR3m0IAznkpdTWdVQ== 0001171843-10-002678.txt : 20101223 0001171843-10-002678.hdr.sgml : 20101223 20101222174525 ACCESSION NUMBER: 0001171843-10-002678 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101221 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20101223 DATE AS OF CHANGE: 20101222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OXIGENE INC CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21990 FILM NUMBER: 101269907 BUSINESS ADDRESS: STREET 1: 701 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 701 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 f8k_122210.htm FORM 8-K
United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 21, 2010

OXiGENE, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
0-21990
13-3679168
(State or other
(Commission File
(I.R.S. Employer
jurisdiction of
Number)
Identification No.)
incorporation)
    
 
701 Gateway Boulevard, Suite 210, South San Francisco, CA 94080
(Address of principal executive offices)

Registrant's telephone number, including area code: (650) 635-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

[_]  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
Item 5.07   Submission of Matters to a Vote of Security Holders.  
 
OXiGENE, Inc. (the "Company") held a Special Meeting of Stockholders on December 21, 2010 at the Company’s offices at 701 Gateway Boulevard, Suite 210, South San Francisco, California, 94080. Of the 107,892,343 shares of the Company’s common stock entitled to vote at the meeting, 78,472,688 shares were represented at the meeting in person or by proxy, constituting a quorum. The voting results are presented below.
 
1.  Approval of an amendment to the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s Common Stock, $0.01 par value per share, at a ratio in the range of 1:2 to 1:20, such ratio to be determined by the Board of Directors:
 
Votes For
 
Votes Against
 
Votes Abstained
  
Broker Non-Votes
  
61,434,835
  
16,765,641
  
272,210
  
0
  
 
2.  Authorization to adjourn this special meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1:
 
Votes For
 
Votes Against
 
Votes Abstained
  
Broker Non-Votes
  
63,087,449
  
15,233,454
  
151,781
  
0
  
 
The reverse stock split authorized by the stockholders pursuant to Proposal 1 has not been implemented at this time. The timing of implementation and the ratio within the approved range applicable to the split remains subject to the determination of the Board of Directors of the Company.
 
 

 
 
 
 
SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  OXiGENE, Inc.
   
Date: December 22, 2010
/s/ James B. Murphy
 
By: James B. Murphy
 
Its: Vice President and Chief
 
Financial Officer

-----END PRIVACY-ENHANCED MESSAGE-----